2026 ICD-10-CM Diagnosis Code E85.81Light chain (AL) amyloidosis
ICD-10-CM Codes›E00–E89›E70-E88›E85
- Billable — Valid for Submission
- CC — Complication or Comorbidity
- Risk Adjusts — HCC 50
- Chronic Condition
E85.81 is a billable ICD-10-CM diagnosis code for light chain (AL) amyloidosis. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 545 through 547. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 10 closely related codes. Coders also document this condition as AL amyloidosis. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified nutritional and metabolic disorders.
For Medicare Advantage risk adjustment, E85.81 maps to CMS-HCC Category 50 (Amyloidosis, Porphyria, and Other Specified Metabolic Disorders) under the V28 model, adding a risk factor of about 0.648 for a community, non-dual, aged beneficiary in payment year 2026.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
E85.81 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2026.
Source: CMS Payment Year 2026 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- AL amyloidosis
- Amyloid light-chain nephropathy
- Amyloid nephropathy
- Light chain disease
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Amyloid Neuropathies, Familial
inherited disorders of the peripheral nervous system associated with the deposition of amyloid in nerve tissue. the different clinical types based on symptoms correspond to the presence of a variety of mutations in several different proteins including transthyretin (prealbumin); apolipoprotein a-i; and gelsolin.Amyloidosis
a group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of amyloid. as the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. various signs and symptoms depend on the location and size of the deposits.Amyloidosis, Familial
diseases in which there is a familial pattern of amyloidosis.Cerebral Amyloid Angiopathy, Familial
a familial disorder marked by amyloid deposits in the walls of small and medium sized blood vessels of cerebral cortex and meninges.Immunoglobulin Light-chain Amyloidosis
a nonproliferative disorder of plasma cells characterized by excessive production and misfolding of immunoglobulin light chains that form insoluble amyloid fibrils (see amyloid deposits) in various tissues. clinical features include liver failure; multiple myeloma; nephrotic syndrome; restrictive cardiomyopathy, and neuropathies.Amyloid
a fibrous protein complex that consists of proteins folded into a specific cross beta-pleated sheet structure. this fibrillar structure has been found as an alternative folding pattern for a variety of functional proteins. deposits of amyloid in the form of amyloid plaques are associated with a variety of degenerative diseases. the amyloid structure has also been found in a number of functional proteins that are unrelated to disease.
Patient EducationClinical
Amyloidosis
Amyloidosis occurs when abnormal proteins called amyloids build up and form deposits. The deposits can collect in organs such as the kidney and heart. This can cause the organs to become stiff and unable to work the way they should.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert E85.81 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code History & ChangesHistory
Replacement E85.81 replaces the following previously assigned code(s):
- E85.8 - Other amyloidosis
Questions About E85.81Overview
What is the ICD-10 code for light chain (AL) amyloidosis?
The ICD-10-CM code for light chain (AL) amyloidosis is E85.81 (sometimes written as E8581). It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
Is E85.81 (Other amyloidosis) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report light chain (AL) amyloidosis on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does E85.81 group to?
When light chain (AL) amyloidosis is the principal diagnosis on an inpatient stay, it groups to MS-DRG 545, 546, 547, with relative weights from 0.8362 to 2.4817 depending on complications. Higher weights mean higher Medicare reimbursement.
Is E85.81 a CC or MCC?
CMS lists E85.81 as a CC (complication or comorbidity) for FY 2026. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 10 closely related codes in its exclusion list.
What is the ICD-9 equivalent of E85.81?
Under the General Equivalence Mappings, light chain (AL) amyloidosis converts to ICD-9-CM 277.39 (amyloidosis NEC). The mapping is approximate, so confirm the match fits the documentation.
What HCC is E85.81?
E85.81 (light chain (AL) amyloidosis) maps to CMS-HCC Category 50 (Amyloidosis, Porphyria, and Other Specified Metabolic Disorders), commonly written as HCC 50, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2026. It mapped to HCC 23 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. It does not map to any RxHCC in the Part D prescription drug model.
Does E85.81 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, E85.81 adds a risk adjustment factor of about 0.648 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.362 to 0.883 depending on the payment segment). HCC 50 sits at the top of its hierarchy, so no other condition category supersedes it. See the full factor table on the HCC 50 category page.
